Everything below concerns ghrelin receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic pentapeptide | GHS-R1a agonist family |
| Receptor target | Ghrelin receptor (GHS-R1a) | G-protein-coupled receptor |
| Sequence length | Five amino acid residues | Includes non-natural residues |
| Primary reported output | Pulsatile growth hormone release | Observed in animal and early human work |
| Molecular formula | C38H49N9O5 | Corresponds to roughly 711.9 g/mol |
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Over 1,000 Kuwaiti civilians were killed by Iraqis. More than 600 Kuwaitis went missing during Iraq's occupation, and approximately 375 remains were found in mass graves in Iraq. The increased importance of air attacks from both coalition warplanes and cruise missiles led to controversy over the number of civilian deaths caused during Desert Storm's initial stages. Within Desert Storm's first 24 hours, more than 1,000 sorties were flown, many against targets in Baghdad. In one noted incident, two USAF stealth planes bombed a bunker in Amiriyah, killing 408 Iraqi civilians. Scenes of burned and mutilated bodies were subsequently broadcast, and controversy arose over the bunker's status, with some stating that it was a civilian shelter, while others contended that it was a center of Iraqi military operations, and that the civilians had been deliberately moved there to act as human shields. The Iraqi government claimed that 2,300 civilians died during the air campaign. A Project on Defense Alternatives study found that 3,664 Iraqi civilians were killed in the conflict. During the nationwide uprisings against the Ba'athist Iraqi government that directly followed the end of the Gulf War in March and April, an estimated 25,000 to 100,000 Iraqis were killed, overwhelmingly civilians. A Harvard University study released in June 1991 predicted that there would be tens of thousands of additional Iraqi civilian deaths by the end of 1991 due to the "public health catastrophe" caused by the destruction of the country's electrical generating capacity.
== Activity == Despite its alternative name (enterokinase), enteropeptidase is a serine protease that catalyses the hydrolysis of peptide bonds in proteins and, unlike other kinases, does not catalyze transfer of phosphate groups. Enteropeptidase exhibits trypsin-like activity, cleaving proteins following a lysine at a specific cleavage site (Asp-Asp-Asp-Asp-Lys). This cleavage results in trypsindependent activation of other pancreatic zymogens, such as chymotrypsinogen, proelastase, procarboxypeptidase and prolipase in the lumen of the gut. As the pro-region of trypsinogen contains this sequence, enteropeptidase catalyses its activation in vivo: trypsinogen → trypsin + pro-region (Val-Asp-Asp-Asp-Asp-Lys)
=== Laboratory findings === Complete blood counts and serum chemistry profiles may be normal in affected horses. Persistent hyperglycemia and glucosuria are very commonly seen. Hyperlipidemia may be present, especially in ponies. Other abnormalities associated with the disease include mild anemia, neurophilia, lymphopenia, eosinopenia, and increased liver enzymes.
=== Modern physics === The idea of hylomorphism can be said to have been reintroduced to the world when Werner Heisenberg invented his duplex world of quantum mechanics. In his 1958 text Physics and Philosophy, Heisenberg states:
Active mobility of these endodermal epithelial cells forms two layers in both the re-aggregate and the re-generating tip of the excised tissue. As these two layers are established, a patterning process takes place to form heads and feet.
Sources: en.wikipedia.org
=== Organ damage === Cardiotoxicity (heart damage) is especially prominent with the use of anthracycline drugs (doxorubicin, epirubicin, idarubicin, and liposomal doxorubicin). The cause of this is most likely due to the production of free radicals in the cell and subsequent DNA damage. Other chemotherapeutic agents that cause cardiotoxicity, but at a lower incidence, are cyclophosphamide, docetaxel and clofarabine. Hepatotoxicity (liver damage) can be caused by many cytotoxic drugs. The susceptibility of an individual to liver damage can be altered by other factors such as the cancer itself, viral hepatitis, immunosuppression and nutritional deficiency. The liver damage can consist of damage to liver cells, hepatic sinusoidal syndrome (obstruction of the veins in the liver), cholestasis (where bile does not flow from the liver to the intestine) and liver fibrosis. Nephrotoxicity (kidney damage) can be caused by tumor lysis syndrome and also due direct effects of drug clearance by the kidneys. Different drugs will affect different parts of the kidney and the toxicity may be asymptomatic (only seen on blood or urine tests) or may cause acute kidney injury. Ototoxicity (damage to the inner ear) is a common side effect of platinum based drugs that can produce symptoms such as dizziness and vertigo. Children treated with platinum analogues have been found to be at risk for developing hearing loss.
==== Sequence-controlled radical polymerization ==== Radical polymerization is one of the most commonly used polymerization methods. About 50% of commercially available polymers are synthesized via radical polymerization. However, the disadvantages of this method are apparent that sequences and polymeric features cannot be well modulated. To overcome these constraints, scientists optimized the employed protocols. The first reported example was the time-controlled sequential addition of highly-reactive N-substituted maleimides in the atom transfer radical polymerization of styrene, which led to programmed sequences of functional monomers. The development of single-molecule addition into atom-transfer radical polymerization (ATRP), which enhances the sequence control of radical polymerization was also reported. Other solutions include the use of intermediate purification steps to isolate the desired oligomer sequence in between subsequent reversible addition−fragmentation chain-transfer polymerization (RAFT-polymerizations). Both flash column chromatography and recycling size exclusion chromatography have been proven successful in this regard. RAFT single unit monomer insertion (SUMI) is recently developed as an emerging technology for precise control of monomer sequence.
== Diagnosis == Epidemiologically, the disorder usually develops slowly and is mainly observed in people over the age of 50. Diagnosis is made on the basis of bone marrow biopsy. Fibrosis grade 2 or 3 defines overt PMF whereas grade 0 or 1 defines prefibrotic primary myelofibrosis. A physical exam of the abdomen may reveal enlargement of the spleen, the liver, or both. Bone marrow biopsy shows fibrosis of the bone marrow. In early stages, this fibrosis is characterised by scattered linear reticulin fibres.
=== Legal status === In the United States, benzodiazepines are Schedule IV drugs under the Federal Controlled Substances Act, even when not on the market (for example, flunitrazepam), with the exception of flualprazolam, etizolam, clonazolam, flubromazolam, and diclazepam which are placed in Schedule I. In Canada, possession of benzodiazepines is legal for personal use. All benzodiazepines are categorized as Schedule IV substances under the Controlled Drugs and Substances Act. In the United Kingdom, benzodiazepines are Class C controlled drugs, carrying the maximum penalty of 7 years imprisonment, an unlimited fine, or both for possession and a maximum penalty of 14 years imprisonment, an unlimited fine, or both for supplying benzodiazepines to others. In the Netherlands, since October 1993, benzodiazepines, including formulations containing less than 20 mg of temazepam, are all placed on List 2 of the Opium Law. A prescription is needed for possession of all benzodiazepines. Temazepam formulations containing 20 mg or greater of the drug are placed on List 1, thus requiring doctors to write prescriptions in the List 1 format. In East Asia and Southeast Asia, temazepam and nimetazepam are often heavily controlled and restricted. In certain countries, triazolam, flunitrazepam, flutoprazepam and midazolam are also restricted or controlled to certain degrees. In Hong Kong, all benzodiazepines are regulated under Schedule 1 of Hong Kong's Chapter 134 Dangerous Drugs Ordinance. Previously only brotizolam, flunitrazepam and triazolam were classed as dangerous drugs.
=== Legal status === On 16 December 2021, and on 24 February 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Padcev, intended for the treatment of adults with urothelial cancer. The applicant for this medicinal product is Astellas Pharma Europe B.V. Enfortumab vedotin was approved for medical use in the European Union in April 2022.
Sources: en.wikipedia.org
5-HTP robustly produces the head-twitch response (HTR) in rodents when administered at relatively high doses. It dose-dependently induces the HTR in mice across a dose range of 50 to 250 mg/kg via intraperitoneal administration, with an inverted U-shaped dose–response curve and maximal induction of the HTR at a dose of 200 mg/kg. Similarly to the case of 5-HTP, intracerebroventricular injection of serotonin, but not peripheral administration of serotonin, produces the HTR. The HTR is induced by serotonergic psychedelics like lysergic acid diethylamide (LSD) and psilocybin and is a behavioral proxy of psychedelic effects. The HTR of 5-HTP is blocked by serotonin 5-HT2A receptor antagonists, which block the hallucinogenic effects of serotonergic psychedelics in humans, is prevented by aromatic L-amino acid decarboxylase (AAAD) inhibitors, which block conversion of 5-HTP into serotonin, and is potentiated by monoamine oxidase A (MAO-A) inhibitors, which prevent the degradation of serotonin and other endogenous tryptamines. It is also suppressed by the serotonin 5-HT1A receptor full agonist 8-OH-DPAT, is greatly augmented by the serotonin 5-HT2C receptor antagonist RS-102221, and is reduced by the trace amine-associated receptor 1 (TAAR1) antagonist EPPTB.
Operation Savannah accelerated the shift of SWAPO's alliances among the Angolan nationalist movements. Until August 1975, SWAPO was theoretically aligned with the MPLA, but in reality PLAN had enjoyed a close working relationship with UNITA during the Angolan War of Independence. In September 1975, SWAPO issued a public statement declaring its intention to remain neutral in the Angolan Civil War and refrain from supporting any single political faction or party. With the South African withdrawal in March, Sam Nujoma retracted his movement's earlier position and endorsed the MPLA as the "authentic representative of the Angolan people". During the same month, Cuba began flying in small numbers of PLAN recruits from Zambia to Angola to commence guerrilla training. PLAN shared intelligence with the Cubans and FAPLA, and from April 1976 even fought alongside them against UNITA. FAPLA often used PLAN cadres to garrison strategic sites while freeing up more of its own personnel for deployments elsewhere. The emerging MPLA-SWAPO alliance took on special significance after PLAN was wracked by a mutiny in Western Province, Zambia between March and April 1976, known as the Shipanga Affair. Relations between SWAPO and the Zambian government were already troubled due to the fact that the growing intensity of PLAN attacks on the Caprivi often provoked retaliatory SADF raids into Zambia.
nuclear equivalence The principle that the nuclei of essentially all differentiated cells of a mature multicellular organism are genetically identical to each other and to the nucleus of the zygote from which they descended; i.e. they all contain the same genetic information on the same chromosomes, having been replicated from the original zygotic set with extremely high fidelity. Even though all adult somatic cells have the same set of genes, cells can nonetheless differentiate into distinct cell types by expressing different subsets of these genes. Though this principle generally holds true, the reality is slightly more complex, as mutations such as insertions, deletions, duplications, and translocations as well as chimerism, mosaicism, and various types of genetic recombination can all cause different somatic lineages within the same organism to be genetically non-identical.
=== First allegation of domestic abuse === In October 2020, Zverev's ex-girlfriend Olga Sharypova, in an article in Racquet magazine by journalist Ben Rothenberg, accused Zverev of physically and emotionally abusing her over the course of their relationship. Sharypova named multiple instances where Zverev allegedly became violent towards her, including punching her in the face during an argument that took place in the pair's hotel room while Zverev was competing at the 2019 Laver Cup. Zverev denied the allegations and issued a statement after Sharypova's initial accusations: "I very much regret that she makes such statements. Because the accusations are simply not true." A second article by Rothenberg about the allegations was released in August 2021, this time in Slate magazine. The second article picked up Sharypova's story where the first left off. It includes this description of the alleged violence escalating in October 2019:
Sources: en.wikipedia.org
It is a synthetic pentapeptide in the growth hormone secretagogue family and acts as an agonist at the ghrelin receptor. It is handled as a laboratory research compound rather than a naturally occurring hormone.
Studies generally report growth hormone as the dominant output, with smaller or absent effects on adrenocorticotropic hormone and prolactin. The size of that separation depends on the assay and the dose examined, so it is best described as relative selectivity.
No natural source has been identified, and the molecule is produced by chemical synthesis. Its non-natural residues distinguish it from endogenous ghrelin even though both engage the same receptor.
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.